Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Karolina Strzebonska"'
Autor:
Karolina Strzebonska, Mateusz Blukacz, Mateusz T. Wasylewski, Maciej Polak, Bishal Gyawali, Marcin Waligora
Publikováno v:
BMC Medicine, Vol 20, Iss 1, Pp 1-16 (2022)
Abstract Background Umbrella clinical trials in precision oncology are designed to tailor therapies to the specific genetic changes within a tumor. Little is known about the risk/benefit ratio for umbrella clinical trials. The aim of our systematic r
Externí odkaz:
https://doaj.org/article/fde121abb1274be4bdfa675f15665d8f
Autor:
Karolina Strzebonska
Publikováno v:
Problemy Pielęgniarstwa, Vol 30, Iss 1-2, Pp 57-58 (2022)
Externí odkaz:
https://doaj.org/article/d372e9a0cae64be88fa1d049234583d6
Autor:
Karolina Strzebonska, Marcin Waligora
Publikováno v:
BMC Medical Ethics, Vol 20, Iss 1, Pp 1-10 (2019)
Abstract Background Novel precision oncology trial designs, such as basket and umbrella trials, are designed to test new anticancer agents in more effective and affordable ways. However, they present some ethical concerns referred to scientific valid
Externí odkaz:
https://doaj.org/article/6fc963a104cc4110a6515ee2c4949d79
Autor:
Mateusz T Wasylewski, Karolina Strzebonska, Magdalena Koperny, Maciej Polak, Jonathan Kimmelman, Marcin Waligora
Publikováno v:
PLoS ONE, Vol 15, Iss 6, p e0234911 (2020)
ObjectivesDrug development trials must fulfill social value requirement but no estimates of value provided by pediatric Phase 1 trials in oncology exist. These trials involve a particularly vulnerable population. Our objective was to assess of surrog
Externí odkaz:
https://doaj.org/article/f7890a9443524ad9b8ed8961926557e2
Autor:
Marcin Waligora, Malgorzata M Bala, Magdalena Koperny, Mateusz T Wasylewski, Karolina Strzebonska, Rafał R Jaeschke, Agnieszka Wozniak, Jan Piasecki, Agnieszka Sliwka, Jerzy W Mitus, Maciej Polak, Dominika Nowis, Dean Fergusson, Jonathan Kimmelman
Publikováno v:
PLoS Medicine, Vol 15, Iss 2, p e1002505 (2018)
BACKGROUND:Pediatric Phase I cancer trials are critical for establishing the safety and dosing of anti-cancer treatments in children. Their implementation, however, must contend with the rarity of many pediatric cancers and limits on allowable risk i
Externí odkaz:
https://doaj.org/article/78717fdf37444366a52d4ee30a8f21ea
Publikováno v:
Medicine, Health Care and Philosophy. 26:233-241
Drug repurposing is a strategy of identifying new potential uses for already existing drugs. Many researchers adopted this method to identify treatment or prevention during the COVID-19 pandemic. However, despite the considerable number of repurposed
Autor:
Jakub Stras, Marcin Waligóra, Maciej Polak, Mateusz T. Wasylewski, Bishal Gyawali, Lucja Zaborowska, Karolina Strzebonska, Emilia Slugocka, Mateusz Blukacz
Publikováno v:
Targeted Oncology
Background For research with human participants to be ethical, risk must be in a favorable balance with potential benefits. Little is known about the risk/benefit ratio for pediatric cancer phase II trials testing targeted therapies. Objective Our ai
Autor:
Maciej Polak, Marcin Waligóra, Karolina Strzebonska, Magdalena Koperny, Jonathan Kimmelman, Mateusz T. Wasylewski
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 6, p e0234911 (2020)
PLoS ONE, Vol 15, Iss 6, p e0234911 (2020)
ObjectivesDrug development trials must fulfill social value requirement but no estimates of value provided by pediatric Phase 1 trials in oncology exist. These trials involve a particularly vulnerable population. Our objective was to assess of surrog
Autor:
Karolina Strzebonska, Marcin Waligóra
Publikováno v:
J Law Med Ethics
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfd7433dd9e6726cf636177770dadf6f
https://ruj.uj.edu.pl/xmlui/handle/item/146431
https://ruj.uj.edu.pl/xmlui/handle/item/146431
Autor:
Mateusz T. Wasylewski, Karolina Strzebonska, Daniel Strech, Nico Riedel, Marcin Waligóra, Lucja Zaborowska, Susanne Wieschowski
Publikováno v:
BMJ Open
ObjectivesTo establish the rates of publication and reporting of results for interventional clinical trials across Polish academic medical centres (AMCs) completed between 2009 and 2013. We aim also to compare the publication and reporting success be